Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/12/2024 | Peer Perform → Underperform | Wolfe Research | |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/16/2024 | $198.00 → $370.00 | Neutral → Buy | Goldman |
| 2/16/2024 | $173.00 | Buy → Neutral | Goldman |
| 2/15/2024 | Peer Perform | Wolfe Research | |
| 12/8/2023 | $171.00 | Equal Weight | Wells Fargo |
| 12/8/2023 | Equal Weight | Wells Fargo | |
| 10/11/2023 | Outperform → Perform | Oppenheimer |
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
SC 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
As former leader of Pfizer's infant nutrition and consumer healthcare businesses, Schulman brings extensive experience in the space, in addition to serving on the boards of several biotech and pharmaceutical companies; This marks ByHeart's first non-executive Board chair appointment In addition to Schulman, ByHeart appoints Niall Mullane, PhD, as Chief Quality Officer to join the experienced executive team; Mullane brings 15 years of quality and food safety experience in the infant nutrition category NEW YORK, March 5, 2024 /PRNewswire/ --Today, ByHeart, the next-generation baby nutrition company, announced the appointment of Amy Schulman, managing partner at Polaris partners, as Chair of th
– Experienced Business and Financial Leader, Kellogg Served as Chief Financial Officer at Biogen, Merck, and Celgene – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience. "Mr. Kellogg joins our Board at a pivotal moment for Alnylam as we continue on the path to achieving our P5x25 strategy and fulfilling our ambition to become a top-tier biopharmaceutical company," said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. "His financial expertise and experi
– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 35% Annual Growth (43% Using Constant Exchange Rate**) – – Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth – – Maintained Strong Balance Sheet with Year-End Cash and Investments Balance of Approximately $2.2 Billion – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2022 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO and provided additional updates on the products' commercial launches. Preliminary Four
– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, Representing 33% Annual Growth – – 2025 Combined Net Product Revenue Guidance** of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability – – Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. In addition, the Company provided 2025 net product revenue, non-GA
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. As part of the presentation, the Company will discuss unaudited fourth quarter and full year 2024 global net product revenues. A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event
GIVLAARI is the first and only therapy in Canada proven to prevent AHP attacks, reduce chronic pain and improve quality of life1 MISSISSAUGA, ON, Dec. 23, 2024 /CNW/ - Alnylam Canada ULC is pleased to announce that GIVLAARI® (givosiran injection) is now funded across Canada through both public and private insurance plans for patients living with acute hepatic porphyria (AHP), including those diagnosed with acute intermittent porphyria (AIP) - the most common type of AHP. GIVLAARI is approved by Health Canada for the treatment of acute hepatic porphyria (AHP) in adults.1 It is the first and only therapy in Canada that is proven to prevent AHP attacks, reduce chronic pain and improve quality
− Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business – − Submitted Regulatory Applications in U.S. and EU for AMVUTTRA® (vutrisiran) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy – − Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of $1,575 Million to $1,650 Million – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. "Alnylam continued to deli
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2024 on Thursday, October 31, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2024 results as well as expectations for the future via conference call on Thursday, October 31, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company's website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event. About Alnylam Phar
− In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively – − In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35% – − Strong Trends of Additive Efficacy on Top of Tafamidis Across Primary and Secondary Endpoints – − Demonstrated Statistically Significant Benefits on Multiple Measures of Disease Progression – − Encouraging Safety and Tolerability Profile, Consistent with Established Profile – − Results from HELIOS-B Si
Wolfe Research downgraded Alnylam Pharma from Peer Perform to Underperform
Scotiabank initiated coverage of Alnylam Pharma with a rating of Sector Outperform
Goldman upgraded Alnylam Pharma from Neutral to Buy and set a new price target of $370.00 from $198.00 previously
Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug OXLUMO (SUPPL-4) with active ingredient LUMASIRAN SODIUM has changed to 'Approval' on 09/19/2023. Application Category: NDA, Application Number: 214103, Application Classification: Labeling
Submission status for ALNYLAM PHARMS INC's drug AMVUTTRA (SUPPL-2) with active ingredient VUTRISIRAN has changed to 'Approval' on 02/16/2023. Application Category: NDA, Application Number: 215515, Application Classification: Labeling